Clinical trial
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain…
NCT00418327 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Completed
Key facts
| NCT number | NCT00418327 |
|---|---|
| Title | Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma |
| Official title | Phase I Studies of TarcevaTM (Erlotinib Hydrochloride, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Brain Tumor, Brain Stem Glioma |
| Intervention type | Drug |
| Interventions | Tarceva (Erlotinib Hydrochloride) |
| Enrollment | 48 |
| Start date | Jun 1, 2005 |
| First posted | Jan 4, 2007 |
| Last update posted | Aug 7, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: